Kornimate/medical-research-clean huggingface dataset:
copperhead envenomation observational study

Conditions: Copperhead Snake Envenomation

Summary: the primary objective of the study is to evaluate the responsiveness and utility of several clinical outcome assessments in the setting of copperhead snakebite. the secondary objective is to characterize the clinical course of signs, symptoms and impairment during the recovery phase of copperhead snakebite.

this observational study will document the patient's recovery from copperhead snakebite. all care provided will be at the discretion of the treating physician in accordance with the local standard of care.

Eligibility criteria:
inclusion criteria: * envenomation by a copperhead snake * presentation for care at a health care facility within 24 hrs of envenomation * envenomation on an extremity distal to the knee or elbow * clinical evidence of venom effect (limb swelling and/or tenderness) * enrollment can be completed within 48 hrs of envenomation prior to discharge * patient is willing and able to complete follow-up schedule of assessments * patient is able to read, comprehend and sign irb approved informed consent * patient is able to read and comprehend written assessment tools * patient is at least 18 yrs old * patient is sober, competent and able to complete verbal and written informed consent exclusion criteria: * patient is pregnant or breastfeeding * patient is a prisoner * patient has distracting injury, condition with acute pain or functional impairment, and/or is unable to make a reliable self-report of status * patient has had previous snake envenomation to any body area within 30 days prior to screening/enrollment, regardless of whether antivenom was administered * patient had an acute traumatic or medical event, surgery, or exacerbation of pre-existing medical or surgical condition effecting the envenomated extremity within 30 days prior to screening/enrollment * patient has participated in a clinical study involving and investigational pharmaceutical product or device within 3 months prior to screening that may have impact on clinical outcomes of snakebite * patient has previously participated in this study * patient is, in the investigator's opinion, otherwise unsuitable for participation. note: treatment with antivenom prior to eligibility evaluation is not an exclusion criterion

Keywords: copperhead snake envenomation
the application of glucose cest mr imaging in brain tumor

Conditions: Magnetic Resonance Imaging

Summary: recently, natural d-glucose was suggested as a potential biodegradable contrast agent. the feasibility of using d-glucose for dynamic perfusion imaging was explored to detect malignant brain tumors based on blood brain barrier breakdown. our study try to evaluate the feasibility of dynamic glucose enhanced(dge) magnetic resonance imaging（mri）in brain tumor, which based on d-glucose weighted chemical exchange saturation transfer (gluceocest).

methods： brain tumor patients were recruited. time-resolved glucose signal changes were detected using chemical exchange saturation transfer (glucocest) mri. dynamic glucose enhanced (dge) mri was used to measure tissue response to an intravenous bolus of d-glucose. during the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade d50 glucose (d50, 25 g of dextrose in 50 ml of water sterile solution), followed by 20 ml of saline solution in 1 arm. the glucose infusion was performed using a power injector at an infusion rate of 0.2 ml/s, corresponding to total infusion times of 250 seconds. performing contrast enhancement based on gd-dtpa in 30 minutes later, which was used for comparison as golden standard. the area of hyperintensity will be measured, which represents the area of brain tumor. differential test and consistency analysis were used for statistical analysis.

Eligibility criteria:
inclusion criteria: * patient must have a brain mass consistent with a primary brain tumor or metastatic brain tumor * able to give consent and willingness to participate in this study. exclusion criteria: * presence of any ferromagnetic implant (cardiac pacemakers, aneurysm clip, etc.) * pregnancy * claustrophobia or anxiety disorder * history of vertigo * persons with diabetes mellitus (self-report or hba1c \>= 6.5%) * sickle cell disease * persons taking prescription medicine for hypertension * blood iron deficiency (hb concentration \< 11 g/dl or hct \< 32%) * if volunteering for mri: history of kidney disease and/or egfr \< 60. * middle-ear disorder * double vision * seizure disorder * multiple myeloma * solid organ transplant * history of severe hepatic disease/liver transplant/pending liver transplant

Keywords: dynamic glucose enhanced human brain tumor chemical exchange saturation transfer
evaluation of the nucleus hybrid™ l24 cochlear implant system

Conditions: Sensorineural Hearing Loss

Summary: the purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 hz) sensorineural hearing loss. delivery of acoustic-electric stimulation will be provided by the nucleus hybrid l24 cochlear implant system.


Eligibility criteria:
inclusion criteria: 1. eighteen years of age or older at the time of implantation. 2. severe to profound (a threshold average of 2000, 3000, \& 4000 hz \> 75db hl) sensorineural hearing loss for frequencies \> 1500 hz. low-frequency thresholds up to and including 500 hz should be no poorer than 60 db hl. 3. consonant nucleus consonant (cnc) monosyllabic word recognition score (mean of two lists) between 10% and 60%, inclusive (i.e., 10% \<= score \<= 60%), in the ear to be implanted. 4. cnc word recognition score in the contralateral ear equal to, or better than, the ear to be implanted but not more than 80%. 5. english spoken as a primary language. exclusion criteria: 1. duration of severe-to-profound hearing loss greater than 30 years. 2. congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age). 3. medical or psychological conditions that contraindicate undergoing surgery. 4. ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 5. conductive overlay of 15 db or greater at two or more frequencies, in the range 250 to 1000 hz. 6. hearing loss of neural or central origin. 7. diagnosis of auditory neuropathy. 8. active middle-ear infection. 9. unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices. 10. unwillingness or inability of the candidate to comply with all investigational requirements. 11. additional handicaps that would prevent or restrict participation in the audiological evaluations.

Keywords: high frequency severe to profound
haemodynamical optimization during brain surgery

Conditions: Brain Edema

Summary: the decision to give fluids perioperatively could be based on methods used to identify preload responsiveness, either invasive or noninvasive estimates of stroke volume variation during mechanical ventilation. this study compares fluid management using invasive measurement spv/ppv (aisys ge) and noninvasive haemodynamic measurement (clarsight, edwards).

the aim of the study is to optimise fluid management and to reduce perioperative risks during brain surgery. adequate perioperative management guided by hemodynamic monitoring can help to reduce the risk of complications and thus potentially improve outcomes. this study compares fluid management algorithms based either on invasive detection of fluid responsiveness using pulse pressure variation (ppv) and systolic pressure variation (spv) values (aisys ge monitoring system) in group a, or on noninvasive measurement of haemodynamics (stroke volume variation (svv), cardiac index (ci) and systemic vascular resistance (svr) values) (clearsight, edwards) in group b.

Eligibility criteria:
inclusion criteria: * glasgow coma scale 15 * asa physical status classification system i-iii * planed surgery for brain tumor to 5 hours * postoperative awakening * sinus rhythm exclusion criteria: * nyha iii, iv * bmi over 40 in females and over 35 in men * awake operation * postoperative artificial ventilation

Keywords: fluid responsiveness haemodynamical monitoring clearsight
contribution of hypnosis during a lumbar puncture.

Conditions: Pain

Summary: the purpose of this study is to assess the effect of hypnosis, as add on therapy, on patients requiring a lumbar puncture (lp) as part of their medical management.

this study will follow the zelen's methodology randomization. it is an add-on study design. 1. the study will be presented to patients as an assessment of their comfort during the lp. the intervention group is not presented to the patient. 2. patients are asked to sign the consent of the standard of care group. 3. randomization into two equally sized groups: * intervention arm : lp with complementary hypnoanalgesia * control arm : lp without complementary hypnoanalgesia 4. patients who have been randomized into the control group, will have lp according to the standard of care. patients who have been randomized into the hypnoanalgesic group will be informed about the hypnoanalgesia intervention and then asked to sign the consent of the hypnosis group. * if the patient accepts, he will benefit from hypnosis during lp. * if the patient refuses, he will re-join the control group without hypnosis. the physicians performing lp will be the same in both groups. a phone call follow-up is scheduled on day 3 and 7 after intervention.

Eligibility criteria:
inclusion criteria: * required a lumbar puncture for diagnosis * affiliated with social security system * patient's written consent exclusion criteria: * lp contraindication * history of previous lp * psychiatric disorder making the realization of a hypnosis irrelevant * cognitive-behavioural abilities that do not allow the completion of the study * persons who are protected under the act. person deprived of liberty by judicial decision * pregnant or breastfeeding woman

Keywords: lumbar puncture anxiety
technology-enabled cardiac rehabilitation through pathway. feasibility, clinical effectiveness and cost-effectiveness

Conditions: Cardiovascular Disease

Summary: the pathway system is designed to help patients remain physically active and maintain a good cardiovascular health. it proposes a novel approach that aims to empower patients to self-manage their cvd, set within a collaborative care context with health professionals. this will be achieved via a patient-centric holistic approach that specifically addresses the above barriers. it involves an internet-enabled and sensor-based home exercise platform. it is represented by several modules with an exercise module as the core component which will provide individualized rehabilitation programs that use regular, socially inclusive exercise sessions as the basis upon which to provide a personalized, comprehensive lifestyle intervention program (managing exercise, smoking, diet, stress, alcohol use etc.) to enable patients to both better understand and deal with their own condition and to lead a healthier lifestyle in general. the goal of this trial is to assess the acceptability, short-term effectiveness on lifestyle and health related physical fitness and cost-effectiveness of the pathway intervention in patients with cvd in a single blind multicentre pilot randomised controlled trial (rct).


Eligibility criteria:
inclusion criteria: * men and women with documented cvd * age 40-80 yrs * patients are on optimal medical treatment and stable with regard to symptoms and pharmacotherapy for at least 4 weeks * patients must have completed the ambulatory cr program and received clinical approval from their treating physician to continue exercising outside the hospital program * internet access at home exclusion criteria: * significant illness during the last 6 weeks * known severe ventricular arrhythmia with functional or prognostic significance * significant myocardial ischemia, hemodynamic deterioration or exercise-induced arrhythmia at baseline testing * cardiac disease that limits exercise tolerance (valve disease with significant hemodynamic consequences, hypertrophic cardiomyopathy etc.) * co-morbidity that may significantly influence one-year prognosis * functional or mental disability that may limit exercise * acute or chronic inflammatory diseases or malignancy, the use of anti-inflammatory drugs or immune suppression * gfr \<25ml/min/1.73m2 * hemoglobin \< 10g/dl * severe chronic obstructive pulmonary disease (fev1 \< 50%) * nyha class 4 * participation in another clinical trial
mediterranean diet and bacterial translocation and immune-activation in patients with hiv

Conditions: Hiv

Summary: evaluate if a change to a mediterranean diet supplemented with nuts and olive oil decreases bacterial translocation and immune activation by a change in the microbiome in successfully treated hiv-1 infected patients with cd4\> 500cells/ml.

mediterranean diet supplemented by nuts and extra virgin olive oil has shown to reduce mortality, cardiovascular diseases, and breast cancer in hiv uninfected individuals. it is likely that changes in the microbiome could play a role in this effect. the goal of the study is to evaluate if a change to a mediterranean diet supplemented with nuts and olive oil decreases bacterial translocation and immune activation by a change in the microbiome in successfully treated hiv-1 infected patients with cd4\> 500cells/ml. one hundred and two patients who will be randomized to continues usual diet or to a mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months. throughout the study a specialized dietician will monitor the patients. blood samples will be collected to assess parameters of bacterial translocation, inflammation and immune activation. to assess compliances with diet, urine samples will be collected too, and stool samples to study changes in gut microbiota. all the samples will be collected at the beginning and 90 days after the inclusion in the study.

Eligibility criteria:
inclusion criteria: * patient ≥ 18 years of age; * to sign voluntary informed consent; * male or female patients with a negative pregnancy test before inclusion in the study; * proven hiv infection (with hiv-1 positive antibodies); * patient should be on stable treatment with cart for at least 1 year * the mean of all cd4 measurements during the year prior to the initiation of cart should be equal to greater than 350 cells / mm3 * the number of cd4 + at the time of recruitment must be equal to or greater than 500 cells / mm3; * hiv viral load should be undetectable at least 6 months prior to study inclusion, and less determinations (occasional blips above the undetectable level are allowed). exclusion criteria: * acquired immunodeficiency syndrome. * active opportunistic diseases. * patients coinfected with hcv or hbv * coagulopathy * renal insufficiency (creatinine\> 1.5 mg / dl) * pregnancy or breastfeeding * inability to sign informed consent * active opportunistic infections, or any active infection or cancer within 30 days prior to the screening visit; * therapy with immunomodulatory agents, including cytokines (eg il-2) and gammaglobulins or chemotherapy within 90 days prior to the screening visit; * use of anticoagulant medication; * use of any type of experimental medication during the 90 days prior to study entry; * uncontrolled psychiatric disorder; * patients with uncontrolled active autoimmune diseases; * usual use of antibiotics

Keywords: microbiota. mediterranean diet bacterial traslocation
study of the efficacy of topical nasal steroids patients with nasal polyps

Conditions: Size of Nasal Polyps; Control of Symptoms

Summary: topical nasal steroid sprays are the mainstream treatment for patients with nasal polyps. polyps tend to recur after surgery and topical nasal steroid sprays are used as the primary medical management to prevent continued growth. more recently high dose topical nasal steroid sprays are used. it is thought that the higher dose will penetrate the sinus cavities at an increased dose and will allow for greater control of polyp growth. safety studies have been performed which have shown no suppression of the pituitary axis with long term high dose topical steroid or changes in intraocular pressure. however, studies in efficacy are limited despite their widespread use. the objective of this study will be to compare the effectiveness of two topical nasal steroid sprays in patients with recurrent nasal polyps.

recruitment plan- patients with nasal polyps who have had sinus surgery at least 3 months prior and documented nasal polyps by endoscopy will be prospectively recruited. this will be a randomized blinded study. patients will be randomized into two groups- group 1 will received topical fluticasone and group 2 will receive topical dexamethasone spray to the nasal cavity. the investigator will be blinded as to which group the subjects are placed in. the medications will be given out from the inland compounding pharmacy located at 24747 redlands blvd, in loma linda. procedures 1. at the time of enrollment nasal endoscopy will be performed to confirm the diagnosis of nasal polyps and to grade the size of the polyps. polyp size will be graded by the following scale: 0- no polyps, 1- polypoid mucosa, 2- polyps within sinus not occluding ostium, 3- polyps occluding ostium filling nasal cavity 2. subjects will be asked to fill out a snot 20 survey before the start of therapy. 3. subjects will be randomized into 2 groups by the flip of a coin. the investigator will be blinded to which group the subject is placed in. the pharmacist (raylene mote, inland compounding pharmacy) who compounds the medications will be the only one aware of which medication was given. 4. subjects will pick up their medication at the inland compounding pharmacy and will be instructed to use the nasal spray- 2 sprays twice a day for 6 weeks. 5. after 6 weeks the subjects will return to the office for repeat nasal endoscopy and will be asked to fill out a snot 20 survey. 6. continued therapy of the nasal steroid spray will be at the discretion of the physician. if subjects do not appear to be responding the nasal steroid spray the medication will be altered as deemed medically necessary.

Eligibility criteria:
inclusion criteria: * subjects with nasal polyps who have had sinus surgery at least 3 months prior to enrollment. exclusion criteria: * allergy to steroids * glaucoma * cataracts

Keywords: nasal polyps nasal steriod sprays
injection of lymphocytes from haplo-identical donor following chemotherapy in patients with high-risk acute myeloblastic leukemia not eligible for an allogeneic hematopoietic stem cell transplantation

Conditions: Acute Myeloid Leukemia (AML)

Summary: patients with high risk aml non eligible for an intensive treatment and for an allogeneic transplantation will be treated with azacitidine and venetoclax. the fourth, fifth and sixth injection of azacitidine will be followed by injection of haplo-identical lymphocytes (hli). this is a single-center phase i study to identify the dose of hli with the most tolerable toxicity. thebayesian continuous reassessment method (crm) will be used


Eligibility criteria:
inclusion criteria: * age ≥18 years * patients with de novo or secondary aml, with an unfavorable or intermediate karyotype (according to the 2017 eln classification), or patients with relapsing aml who may receive second-line treatment * not candidates for intensive induction, for the following reasons * 75 years or ≥ 18 to 74 years and at least one of the following comorbidities: ps ≥ 2 or a history of heart failure requiring treatment or lvef ≤ 50% or chronic stable angina or fev1 ≤ 65% or dlco ≤ 65% or creatinine clearance \ 1.5 n or other comorbidities that the hematologist considers incompatible with intensive treatment * ineligible for a classic allogeneic hematopoietic stem cell transplant due to the presence of co-morbidities or too high a risk of toxicity \>70 years old or at least one of the following comorbidities: ps ≥ 2 or a history of heart failure requiring treatment or lvef ≤ 50% or chronic stable angina or fev1 ≤ 65% or dlco ≤ 65% or creatinine clearance \ 1.5 n * may receive chemotherapy with hypomethylating agents have a partially compatible (haplo-identical) major family donor (≥18 years old) eligible for lymphocyte donation. exclusion criteria: * aml with favorable karyotype (according to eln 2017) in rc1 * patient with refractory or progressive aml * other progressive cancer in progress * karnosky index \ 2 * severe hepatic function disturbance: transaminases\> 5 n, hyperbilirubinemia\> 30 µm / l * severe infection requiring hospitalization. * psychiatric illness compromising the understanding of the information or the carrying out of the study. * woman of childbearing potential and refusing an effective method of contraception. * minor * adult under tutorship or curatorship, under legal protection or under family authorization * minor family donor (\<18 years old)
a study of mabthera/rituxan (rituximab) in combination with methotrexate in patients with rheumatoid arthritis and inadequate response to dmard therapy

Conditions: Rheumatoid Arthritis

Summary: this study will evaluate the efficacy and safety of mabthera/rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 dmard treatment. all patients will receive mabthera (1000mg iv infusion) on days 1 and 15, and methotrexate (10-25mg po) weekly. the anticipated time on study treatment is 3-12 months.


Eligibility criteria:
inclusion criteria: * adult patients, 18-80 years of age; * rheumatoid arthritis after inadequate response to \>=1 dmard treatment; * active disease; * dmards other than methotrexate withdrawn for at least 4 weeks prior to start of study treatment. exclusion criteria: * autoimmune disease other than rheumatoid arthritis; * bone/joint surgery within 8 weeks prior to screening, or joint surgery planned within 24 weeks of mabthera infusion; * concurrent treatment with any dmard or antitnf-alfa; * intra-articular or parenteral corticosteroids within 4 weeks prior to screening.
the coronavirus impact scale validity and reliability study

Conditions: TURKISH VALIDITY AND RELIABILITY STUDY OF THE CORONAVIRUS IMPACT SCALE

Summary: this research; the turkish validity and reliability study of the "coronavirus impact scale" developed by stoddard and kaufman (2020) will be conducted in order to bring a new measurement tool to our country.

this research; the turkish validity and reliability study of the "coronavirus impact scale" developed by stoddard and kaufman (2020) will be conducted in order to bring a new measurement tool to our country. method: this research was planned as a methodological study. research question: is the "coronavirus impact scale" a valid and reliable measurement tool for turkish society?

Eligibility criteria:
inclusion criteria: * at least 18 years old, * at least primary school graduate, * able to communicate verbally and * persons who agree to participate in the research will be included in the research. exclusion criteria: * psychiatric illness and unable to communicate, * having a language problem * persons who do not have the skills to read and understand the questionnaire will be excluded from the research.

Keywords: coronovirus, impact, reliability, validity, measuring tool, nursing.